Want to see TSE:CBST full AI Analyst Report?
Top Page
Cannabist Company Holdings
(NEO-L:CBST)
Select Model
Select Model
Rating:37Underperform
Price Target:
C$0.52
▼(-6.43% Downside)
Action:Reiterated
Date:12/11/25
Cannabist Company Holdings is facing severe financial difficulties, with declining revenues, high leverage, and negative equity. The technical analysis indicates an overbought condition without clear momentum, and the valuation reflects unprofitability. These factors contribute to a low overall stock score.
Positive Factors
Product Diversity
A diverse product range allows Cannabist Company Holdings to cater to various consumer preferences, enhancing market reach and resilience against market fluctuations.
Negative Factors
Declining Revenue
Declining revenues indicate challenges in market demand or competitive pressures, which can undermine long-term financial stability and growth prospects.
Read all positive and negative factors
Positive Factors
Negative Factors
Product Diversity
A diverse product range allows Cannabist Company Holdings to cater to various consumer preferences, enhancing market reach and resilience against market fluctuations.
Read all positive factors
Cannabist Company Holdings (CBST) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$227.80M
Dividend YieldN/A
Average Volume (3M)0.00
Price to Earnings (P/E)―
Beta (1Y)N/A
Revenue Growth-26.72%
EPS Growth-32.38%
CountryCA
Employees1,681
SectorGeneral
Sector StrengthN/A
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)-0.38
Shares Outstanding535,360,840
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-1.06
Price to Sales (P/S)0.07
P/FCF Ratio-1.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.13
Revenue Forecast (FY)C$335.98M
Cannabist Company Holdings Business Overview & Revenue Model
Company Description
The Cannabist Company Holdings, Inc. engages in the production and sale of cannabis-based medicinal products. Its brands include Classix, Triple Seven, Seed and Stain, Amber, PRESS, and Hedy. The company was founded by Nicholas Keane Vita and Mich...
How the Company Makes Money
Cannabist Company Holdings generates revenue primarily through the sale of its cannabis products in both medical and recreational markets. The company operates retail dispensaries, which serve as direct sales points to consumers, and also engages ...
Cannabist Company Holdings Earnings Call Summary
Earnings Call Date:Aug 07, 2025
(Q2-2025)
| Next Earnings Date:Aug 17, 2026
Earnings Call Sentiment Neutral
The earnings call reflected a mixed performance with significant operational improvements and strategic market exits, but also faced challenges with revenue decline and margin pressures. The company is focusing on liquidity management and operational simplification to address these issues.Positive Updates
Debt Restructuring Completion
Completed a debt restructuring transaction, extending the maturity of $271 million of senior debt obligations until at least December 2028.
Negative Updates
Revenue Decline
Second quarter revenue was $87 million, a decrease of 1% from the first quarter, mainly due to the sale of two retail locations in California and ongoing pricing pressure.
Read all updates
Q2-2025 Updates
Positive
Negative
Debt Restructuring Completion
Completed a debt restructuring transaction, extending the maturity of $271 million of senior debt obligations until at least December 2028.
Read all positive updates
Company Guidance
During The Cannabist Company's second quarter 2025 earnings call, several key metrics and strategic initiatives were highlighted. The company reported $87 million in revenue, a slight 1% decrease from the previous quarter, primarily due to asset sales and pricing pressures. They achieved an adjusted EBITDA of $8.5 million, with a 30 basis point improvement in margin to 9.8%. Wholesale revenue increased by 16% sequentially, contributing to 21% of total revenue, despite a decline in wholesale gross margin due to inventory reduction efforts. The company is actively managing liquidity, reducing costs, and restructuring operations, including divesting assets in Florida, California, Illinois, and Pennsylvania. They closed the quarter with $15.5 million in cash and plan to enhance revenue streams through new agreements in Pennsylvania. Additionally, the company aims to maintain CapEx below $3 million per quarter, focusing on new store openings and operational enhancements.Cannabist Company Holdings Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
25
Negative
Cash Flow
40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 349.84M | 458.72M | 511.33M | 491.31M | 456.03M | 188.99M |
| Gross Profit | 103.25M | 168.30M | 179.97M | 136.13M | 146.92M | 52.68M |
| EBITDA | -49.43M | 28.61M | -51.30M | -282.36M | -63.14M | -115.66M |
| Net Income | -178.96M | -105.89M | -175.71M | -399.52M | -141.84M | -100.85M |
Balance Sheet | ||||||
| Total Assets | 536.51M | 696.17M | 823.11M | 994.28M | 1.37B | 727.53M |
| Cash, Cash Equivalents and Short-Term Investments | 17.76M | 33.61M | 36.91M | 48.13M | 82.09M | 61.11M |
| Total Debt | 443.05M | 478.42M | 546.32M | 566.97M | 420.75M | 295.21M |
| Total Liabilities | 689.46M | 726.23M | 757.76M | 787.47M | 824.57M | 440.58M |
| Stockholders Equity | -151.68M | -28.69M | 66.53M | 213.19M | 570.62M | 306.82M |
Cash Flow | ||||||
| Free Cash Flow | -37.16M | -29.21M | -2.50M | -179.70M | -132.64M | -97.42M |
| Operating Cash Flow | -31.37M | -23.38M | 7.47M | -106.99M | -518.40K | -52.27M |
| Investing Cash Flow | 36.15M | 30.98M | -3.50M | -72.34M | -189.67M | -24.02M |
| Financing Cash Flow | -18.95M | -9.00M | -14.12M | 147.59M | 200.66M | 90.00M |
Cannabist Company Holdings Technical Analysis
Negative
0.56
Price Trends
0.56
Positive
0.56
Negative
0.56
Negative
Market Momentum
>-0.01
Neutral
100.00
Negative
66.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:CBST, the sentiment is Negative. The current price of 0.56 is below the 20-day moving average (MA) of 0.56, above the 50-day MA of 0.56, and below the 200-day MA of 0.56, indicating a neutral trend. The MACD of >-0.01 indicates Neutral momentum. The RSI at 100.00 is Negative, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:CBST.
Cannabist Company Holdings Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | C$250.54M | 7.29 | 19.79% | ― | 22.20% | 47.62% | |
67 Neutral | C$173.86M | 14.24 | 11.63% | ― | 19.35% | -26.04% | |
56 Neutral | C$139.97M | -123.74 | 1.34% | ― | 24.36% | 65.65% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
47 Neutral | C$139.79M | -1.33 | 66.16% | ― | 3.04% | -47.28% | |
37 Underperform | C$227.80M | -0.08 | 188.90% | ― | -26.72% | -32.38% |
* General Sector Average
TSE:CBST
Cannabist Company Holdings
0.56
0.00
0.00%
TSE:JUSH
Jushi Holdings
0.70
0.28
66.67%
TSE:XLY
Auxly Cannabis Group
0.18
0.06
52.17%
TSE:GRIN
Grown Rogue International
0.56
0.06
12.00%
TSE:LOVE
Cannara Biotech
1.76
0.31
21.38%
Cannabist Company Holdings Corporate Events
Business Operations and StrategyM&A Transactions
Cannabist Company Sells Virginia Assets to Curaleaf for $110 Million
Neutral
Dec 2, 2025
The Cannabist Company Holdings Inc. has announced an agreement to sell its Virginia-based cannabis operations to Curaleaf Holdings Inc. for $110 million. This transaction is part of a strategic review by the company’s board to address operat...
Financial Disclosures
The Cannabist Company to Announce Q3 2025 Financial Results
Neutral
Nov 4, 2025
The Cannabist Company announced it will release its third-quarter 2025 financial results on November 10, 2025, after the U.S. financial markets close. This announcement is significant as it provides stakeholders with insights into the company̵...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.